4/21
04:02 pm
vrdn
Kopp Family Office Trims $3.5 Million Worth of Viridian Therapeutics Stake -- What Investors Should Know [Yahoo! Finance]
Neutral
Report
Kopp Family Office Trims $3.5 Million Worth of Viridian Therapeutics Stake -- What Investors Should Know [Yahoo! Finance]
4/21
09:20 am
vrdn
Viridian Therapeutics (VRDN) had its price target lowered by Truist Financial Corporation from $36.00 to $33.00. They now have a "buy" rating on the stock.
Medium
Report
Viridian Therapeutics (VRDN) had its price target lowered by Truist Financial Corporation from $36.00 to $33.00. They now have a "buy" rating on the stock.
4/21
06:32 am
vrdn
Analysts Have Just Cut Their Viridian Therapeutics, Inc. (NASDAQ:VRDN) Revenue Estimates By 20% [Yahoo! Finance]
Medium
Report
Analysts Have Just Cut Their Viridian Therapeutics, Inc. (NASDAQ:VRDN) Revenue Estimates By 20% [Yahoo! Finance]
4/9
08:51 am
vrdn
Viridian Therapeutics price target lowered to $36 from $40 at Truist [Yahoo! Finance]
Medium
Report
Viridian Therapeutics price target lowered to $36 from $40 at Truist [Yahoo! Finance]
4/8
08:49 am
vrdn
Viridian Therapeutics (VRDN) had its price target lowered by Wedbush from $37.00 to $31.00. They now have an "outperform" rating on the stock.
Low
Report
Viridian Therapeutics (VRDN) had its price target lowered by Wedbush from $37.00 to $31.00. They now have an "outperform" rating on the stock.
4/8
05:41 am
vrdn
A Look At Viridian Therapeutics (VRDN) Valuation After A Sharp Multi-Month Share Price Pullback [Yahoo! Finance]
Medium
Report
A Look At Viridian Therapeutics (VRDN) Valuation After A Sharp Multi-Month Share Price Pullback [Yahoo! Finance]
4/7
02:33 pm
vrdn
Viridian Therapeutics (VRDN) had its price target lowered by The Goldman Sachs Group, Inc. from $36.00 to $31.00. They now have a "buy" rating on the stock.
Low
Report
Viridian Therapeutics (VRDN) had its price target lowered by The Goldman Sachs Group, Inc. from $36.00 to $31.00. They now have a "buy" rating on the stock.
4/7
09:17 am
vrdn
Viridian Therapeutics (VRDN) had its price target lowered by Royal Bank Of Canada from $42.00 to $30.00. They now have an "outperform" rating on the stock.
Low
Report
Viridian Therapeutics (VRDN) had its price target lowered by Royal Bank Of Canada from $42.00 to $30.00. They now have an "outperform" rating on the stock.
4/2
01:17 pm
vrdn
Viridian Therapeutics, Inc. (VRDN) Discusses Positive Topline Results from Elegrobart REVEAL-1 Phase III Trial in Active Thyroid Eye Disease Transcript [Seeking Alpha]
Low
Report
Viridian Therapeutics, Inc. (VRDN) Discusses Positive Topline Results from Elegrobart REVEAL-1 Phase III Trial in Active Thyroid Eye Disease Transcript [Seeking Alpha]
4/1
08:34 am
vrdn
Viridian's REVEAL-1: Clinically Active But Not Market-Dominating, Shares React Badly [Seeking Alpha]
Low
Report
Viridian's REVEAL-1: Clinically Active But Not Market-Dominating, Shares React Badly [Seeking Alpha]
3/31
12:49 pm
vrdn
Viridian Therapeutics (VRDN) had its price target lowered by The Goldman Sachs Group, Inc. from $41.00 to $36.00. They now have a "buy" rating on the stock.
Low
Report
Viridian Therapeutics (VRDN) had its price target lowered by The Goldman Sachs Group, Inc. from $41.00 to $36.00. They now have a "buy" rating on the stock.
3/31
11:00 am
vrdn
Viridian Therapeutics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Medium
Report
Viridian Therapeutics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
3/31
10:20 am
vrdn
Viridian Therapeutics (VRDN) had its price target lowered by Wells Fargo & Company from $29.00 to $20.00. They now have an "equal weight" rating on the stock.
Medium
Report
Viridian Therapeutics (VRDN) had its price target lowered by Wells Fargo & Company from $29.00 to $20.00. They now have an "equal weight" rating on the stock.
3/31
10:20 am
vrdn
Viridian Therapeutics (VRDN) had its price target lowered by Wedbush from $44.00 to $37.00. They now have an "outperform" rating on the stock.
Medium
Report
Viridian Therapeutics (VRDN) had its price target lowered by Wedbush from $44.00 to $37.00. They now have an "outperform" rating on the stock.
3/31
08:02 am
vrdn
Viridian Therapeutics (VRDN) had its price target lowered by HC Wainwright from $34.00 to $22.00. They now have a "buy" rating on the stock.
Medium
Report
Viridian Therapeutics (VRDN) had its price target lowered by HC Wainwright from $34.00 to $22.00. They now have a "buy" rating on the stock.
3/30
02:17 pm
vrdn
Viridian Therapeutics (VRDN) had its price target lowered by Needham & Company LLC from $42.00 to $32.00. They now have a "buy" rating on the stock.
Low
Report
Viridian Therapeutics (VRDN) had its price target lowered by Needham & Company LLC from $42.00 to $32.00. They now have a "buy" rating on the stock.
3/30
12:43 pm
vrdn
Viridian Therapeutics shares fall over 30% after trial data disappoints [Yahoo! Finance]
Low
Report
Viridian Therapeutics shares fall over 30% after trial data disappoints [Yahoo! Finance]
3/30
07:24 am
vrdn
Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL-1 Clinical Trial in Active Thyroid Eye Disease [Yahoo! Finance]
Medium
Report
Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL-1 Clinical Trial in Active Thyroid Eye Disease [Yahoo! Finance]
3/30
07:01 am
vrdn
Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL-1 Clinical Trial in Active Thyroid Eye Disease
High
Report
Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL-1 Clinical Trial in Active Thyroid Eye Disease
3/21
06:47 pm
vrdn
This Fund Just Cut a Viridian Stock Position by Over $80 Million. Here's What Investors Should Know [Yahoo! Finance]
Low
Report
This Fund Just Cut a Viridian Stock Position by Over $80 Million. Here's What Investors Should Know [Yahoo! Finance]
3/11
09:03 am
vrdn
Viridian Therapeutics (VRDN) had its "outperform" rating reaffirmed by Wedbush. They now have a $44.00 price target on the stock.
Low
Report
Viridian Therapeutics (VRDN) had its "outperform" rating reaffirmed by Wedbush. They now have a $44.00 price target on the stock.
2/27
07:03 pm
vrdn
What Viridian Therapeutics (VRDN)'s 2025 Losses and Thyroid Eye Disease Milestones Mean For Shareholders [Yahoo! Finance]
Low
Report
What Viridian Therapeutics (VRDN)'s 2025 Losses and Thyroid Eye Disease Milestones Mean For Shareholders [Yahoo! Finance]
2/27
01:33 pm
vrdn
Viridian Therapeutics (VRDN) had its price target lowered by Royal Bank Of Canada from $45.00 to $42.00. They now have an "outperform" rating on the stock.
Medium
Report
Viridian Therapeutics (VRDN) had its price target lowered by Royal Bank Of Canada from $45.00 to $42.00. They now have an "outperform" rating on the stock.
2/26
07:11 am
vrdn
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2025 Financial Results [Yahoo! Finance]
Medium
Report
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2025 Financial Results [Yahoo! Finance]
2/26
07:01 am
vrdn
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2025 Financial Results
Medium
Report
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2025 Financial Results